Feeds:
Posts
Comments

Posts Tagged ‘molecular tumor board’

Real Time Conferecence Coverage: Advancing Precision Medicine Conference Philadelphia PA November 1,2 2024  Deliverables

Posted in Artificial Intelligence Applications in Health Care, Big Data, Bio Instrumentation in Experimental Life Sciences Research, Cancer Genomics, Cancer-Immune Interactions, Circulating Tumor Cells (CTC), Conference Coverage with Social Media, Deep Learning, Immuno-Oncology & Genomics, Machine Learning, Personalized and Precision Medicine & Genomic Research, Pharmacogenomics, Precision Cancer Medicine, Proteomics, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, Transcriptomics, Uncategorized, tagged , , , , , , , , , on October 21, 2025| 1 Comment »

Real Time Conferecence Coverage: Advancing Precision Medicine Conference Philadelphia PA November 1,2 2024  Deliverables

Curator: Stephen J. Williams, Ph.D.

Below are deliverables in form of real Time conference coverage from the Advancing Precision Medicine Confererence held this year in Philadelphia, PA.  The meeting brought together scientists and clinicians to discuss the challenges faced in implementing genomics and proteomics into precision medicine decision making workflow.  As summarized by a future release at the 2025 ASCO, there are many issues and hindrances to incorporating data obtained from sequencing to make a personalized medicine strategy.  The meeting focused on two main disease states: oncology and cardiovascular however most of  the live meeting notes are from the oncology tract.  In general it was discussed there are three areas which need to be addressed to correctly and more frequently incorporate precision medicine and genomic panel testing into clinical decision making workflow:

  1.  access to testing panels and testing methodology for both doctors and patients
  2. expert interpretation of results including algorithms needed to analyze the data
  3. more education of molecular biology and omics data and methodology in medical school to address knowledge gaps between clinicians and scientists

The issues can be summarized by a JCO report to ASCO in 2022:

 Helen Sadik, PhD, Daryl Pritchard, PhD https://orcid.org/0000-0003-2675-0371 dpritchard@personalizedmedicinecoalition.org, Derry-Mae Keeling, BSc, Frank Policht, PhD, Peter Riccelli, PhD, Gretta Stone, BS, Kira Finkel, MSPH, Jeff Schreier, MBA, and Susanne Munksted, MS.  Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer. 2022: JCO Precision Oncology; Volume 6. https://doi.org/10.1200/PO.22.00246

Personalized medicine presents new opportunities for patients with cancer. However, many patients do not receive the most effective personalized treatments because of challenges associated with integrating predictive biomarker testing into clinical care. Patients are lost at various steps along the precision oncology pathway because of operational inefficiencies, limited understanding of biomarker strategies, inappropriate testing result usage, and access barriers. We examine the impact of various clinical practice gaps associated with diagnostic testing-informed personalized medicine strategies on the treatment of advanced non–small-cell lung cancer (aNSCLC).

The authors used a  Diaceutics’ Data Repository, a multisource database including commercial and Medicare claims and laboratory data from over 500,000 patients with non–small-cell lung cancer in the United States. They  analyzed the number of patients with newly diagnosed aNSCLC who could have, but did not, benefit from a personalized treatment. The analysis was focused on identifying the gaps and at which steps during care did gaps existed which precipitated either lack of use of precision medicine testing or incorrect interpretation of results.

Their conclusions were alarming:

Most patients with aNSCLC eligible for precision oncology treatments do not benefit from them because of clinical practice gaps. This finding is likely reflective of similar gaps in other cancer types. An increased understanding of the impact of each practice gap can inform strategies to improve the delivery of precision oncology, helping to fully realize the promise of personalized medicine.

The links to the live meeting notes are given below and collection of tweets follow (please note this meeting did not have a Twitter hashtag)

Real Time Coverage Advancing Precision Medicine Annual Conference, Philadelphia PA November 1,2 2024

https://pharmaceuticalintelligence.com/2024/11/01/real-time-coverage-advancing-precision-medicine-annual-conference-philadelphia-pa-november-12-2024/

Real Time Coverage Morning Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 1 2024

https://pharmaceuticalintelligence.com/2024/11/01/real-time-coverage-morning-session-on-precision-oncology-advancing-precision-medicine-annual-conference-philadelphia-pa-november-1-2024/

Real Time Coverage Afternoon Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 1 2024

https://pharmaceuticalintelligence.com/2024/11/01/real-time-coverage-afternoon-session-on-precision-oncology-advancing-precision-medicine-annual-conference-philadelphia-pa-november-1-2024/ 

Real Time Coverage Morning Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 2 2024

https://pharmaceuticalintelligence.com/2024/11/04/real-time-coverage-morning-session-on-precision-oncology-advancing-precision-medicine-annual-conference-philadelphia-pa-november-2-2024/ 

Tweet Collection

Tweet Collection Advancing Precision Medicine Conference November 1,2 2024 Philadelphia PA

 

Read Full Post »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session October 4 2025

Posted in Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence Applications in Health Care, Artificial Intelligence in CANCER, Artificial Intelligence in Medicine - Application for Diagnosis, Artificial Intelligence in Medicine - Applications in Therapeutics, Bio-Ethics, BioBanking, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Biological Networks, Biological Networks, Gene Regulation and Evolution, Cancer Genomics, Cancer Informatics, Clinical Diagnostics, Foundations for supporting Science and Education, Gene Regulation, Health Care System by Country, India, Intelligent Information Systems, Machine Learning, Natural Language Processing (NLP), Personalized and Precision Medicine & Genomic Research, Personalized Medicine Coalition, Precision Cancer Medicine, Proteomics, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Scientific & Biotech Conferences: Press Coverage, tumor microenvironment, tagged , , , , , , , , , , , , , , , , , , , , , on October 4, 2025| Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Afternoon Session  October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

1:40 – 2:30

AI in Precision Medicine

Dr. Ganhui Lan

Dr. Ganhui Lan VP, Data Science & Machine Learning, Genentech

Dr. Xiaoyan Wang

Dr. Xiaoyan Wang Research Professor, Department of Health Policy and Management, Tulane University Chief Scientist, SVP, Intelligent Medical Objects

Dr. Ahmad P. Tafti

Dr. Ahmad P. Tafti Assistant Professor, School of Computing and Information,School of Health and Rehabilitation Sciences, University of Pittsburgh Interim Director, Division of Scientific Affairs, Computational Pathology AI Center of Excellence

Jen Gilburg

Jen Gilburg (moderator)Deputy Secretary of Technology and Entrepreneurship, Dept. of Community and Economic Development, Commonwealth of Pennsylvania

  • AI will help reduce time for drug development especially in early phase of discovery but eventually help in all phases
  • Ganhui: for drug regulators might be more amenable to AI in clinical trials; AI may be used differently by clinicians
  • nonprofit in Philadelphia using AI to repurpose drugs (this site has posted on this and article will be included here)
  • Ganhui: top challenge of AI in Pharma; rapid evolution of AI and have to have core understanding of your needs and dependencies; realistic view of what can be done; AI has to have iterative learning; also huge vertical challenge meaning how can we allign the use of AI through the healthcare vertical layer chain like clinicians, payers, etc.
  • Ganhui sees a challenge for health companies to understand how to use AI in business to technology; AI in AI companies is different need than AI in healthcare companies
  • 95% of AI projects not successful because most projects are very discrete use

2:00-2:20

Building Precision Oncology Infrastructure in Low- and Middle-Income Countries

Razelle Kurzrock, MD

Sewanti Limaye, MD, Director, Medical & Precision Oncology; Director Clinical and Translational Oncology Research, Sir HN Reliance Foundation Hospital & Research Centre, Mumbai, India; Founder, Nova Precision AI; Co-Founder, Iylon Precision Oncology; Co-Chair, Asia Pacific Coalition Against Lung Cancer; Co-Chair,  Asia Pacific Immuno-Oncology; Member,  WIN Consortium

  • globally 60 precision initiatives but there really are because many in small countries
  • three out of five individuals in India die of cancer
  • precision medicine is a must and a hub and spoke model is needed in these places; Italy does this hub and spoke; spokes you enable the small places and bring them into the network so they know how and have access to precision medicine
  • in low income countries the challenge starts with biopsy: then diagnosis and biomarker is issue; then treatment decision a problem as they may not have access to molecular tumor boards
  • prevention is always a difficult task in LMICs (low income)
  • you have ten times more patients in India than in US (triage can be insurmountable)
  • ICGA Foundation: Indian Cancer Genome Atlas
  • in India mutational frequencies vary with geographical borders like EGFR mutations or KRAS mutations
  • genomic landscape of ovarian cancer in India totally different than in TCGA data
  • even different pathways are altered in ovarian cancer seen in North America than in India
  • MAY mean that biomarker panels need to be adjusted based on countries used in
  • the molecular data has to be curated for the India cases to be submitted to a tumor board
  • twenty diagnostic tests in market like TruCheck for Indian market; uses liquid biopsy
  • they are also tailoring diagnostic and treatment for India getting FDA fast track approvals

2:20-2:40

Co-targeting KIT/PDGRFA and Genomic Integrity in Gastrointestinal Stromal Tumors

Razelle Kurzrock, MD

Lori Rink, PhD, Associate Professor, Fox Chase Cancer Center

  • GIST are most common nesychymal tumor in GI tract
  • used to be misdiagnosed; was considered a leimyosarcoma
  • very asymptomatic tumors and not good prognosis
  • very refractory to genotoxic therapies
  • RTK KIT/PDGFRA gain of function mutations
  • Gleevec imatinib for unresectable GIST however vast majority of even responders become resistant to therapy and cancer returns
  • there is a mutation map for hotspot mutations and sensitivity for gleevec
  • however resistance emerged to ripretinib; in ATP binding pocket
  • over treatment get a polyclonal resistance
  • performed a kinome analysis; Wee1 looked like a potential target
  • mouse studies (80 day) showed good efficacy
  • avapiritinib ahs some neurotox and used in PDGFRA mut GIST model which is resistant to imitinib
  • but if use Wee1 inhibitor with TKI can lower dose of avapiritinib
  • cotargeting KIT/PDGFRA and WEE1 increases replicative stress
  • they are using PDX models to test these combinations
  • combination creates genomic instability

 

Read Full Post »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Early Morning Session Track 1 October 4 2025

Posted in Anti-tumor necrosis factor drugs (TNF inhibitors), BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Cancer Genomics, Cancer Informatics, Cancer-Immune Interactions, Circulating Tumor Cells (CTC), Clinical Genomics, COVID-19, Evidence-based decision-making, Genomic Expression, Immuno-Oncology & Genomics, Immunotherapy, Inflammasome, KRAS Mutation, Metabolic Immuno-Oncology, Microbiology, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, SARS-CoV-2 Viral Variants, TP53 - Germline mutations, Translational Research, Translational Science, tagged , , , , , , , , , on October 4, 2025| Leave a Comment »

Real Time Conference Coverage: Advancing Precision Medicine Conference, Early Morning Session Track 1 October 4 2025

Reporter: Stephen J. Williams, PhD

Leaders in Pharmaceutical Business Intellegence will be covering this conference LIVE over X.com at

@pharma_BI

@StephenJWillia2

@AVIVA1950

@AdvancingPM

using the following meeting hashtags

#AdvancingPM #precisionmedicine #WINSYMPO2025

 

8:55 – 10:35

SESSION 1

Precision For All:

Global Access, Real Cases, and Implementation Science

 

8:55-9:15

Results and Future Direction from WIN’s Data Science Paper

Razelle Kurzrock, MD

Gerald Batist, MD, Director, Segal Cancer Centre, Jewish General Hospital; Director, McGill Centre for Translational Research in Cancer; Professor, Department of Oncology, McGill University

9:15-9:55

When Precision Gets Personal: WIN Consortium International Molecular Tumor Board Live

Andrea Ferreira-Gonzalez

Wafik S. El-Deiry, MD, PhD, FACP, Chair, WIN Consortium, Director, Legorreta Cancer Center Brown University, Director, Joint Program in Cancer Biology, Brown University and Brown University Health; Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University; Attending Physician, Hematology/Oncology, Brown University Health Mencoff Family University; Professor of Medical Science, Professor of Pathology and Laboratory Medicine, Brown University; Professor, American Cancer Society Research Professor

Razelle Kurzrock, MD

Razelle Kurzrock, MD, FACP, Chief Medical Officer, WIN Consortium; Professor of Medicine, Associate Director, Clinical Research, Linda T. and John A. Mellowes Endowed Chair of Precision Oncology, MCW Cancer Center and Linda T. & John A. Mellowes Center for Genomic Sciences and Precision Medicine

Notes from Live Tumor Board from Live Tweets

Tumor board Live… Molecular profiling great for identifying synthetic lethal combinations work very well… Many oncologist not accepting recommendations of molec tumor board

@AVIVA1950
@Pharma_BI
@AdvancingPM
Tumor board Live . Oncologists don’t always accept tumor board recommendations based on molecular profiling… Dr Baptiste at first felt constrained to use single agent but WINTER combo trial with molec profiling better

@Pharma_BI
Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

@Pharma_BI
@AVIVA1950
@AdvancingPM
Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

@Pharma_BI
@AVIVA1950
@AdvancingPM
Tumor board Live… Oncologist may give pushback when molecular therapeutic targets identified.. like when methylomics give a result and tumor board suggest temazolamide

@Pharma_BI
@AVIVA1950
@AdvancingPM
Pemetrexemed not always working but MTAP inhibitions may work

@Pharma_BI
@AVIVA1950
@AdvancingPM
Tumor board Live… Discussion of ovarian cancer case women first presented with CRC BRCA mut but failed PARP inhibitor board is looking at immunotherapy NGS IHC performed

@Pharma_BI
@AdvancingPM

#WINconsortium

Fusions being detected by RNAseq at rate of 100 per month

@AVIVA1950
@Pharma_BI
@AdvancingPM
Tumor board Live…. Theranostics are becoming part of molec tumor board … Radio labeled dual diagnostic therapeutic antibodies

@Pharma_BI
@AVIVA1950
@AdvancingPM
Tumor board Live… Molecular profiling great for identifying synthetic lethal combinations work very well… Many oncologist not accepting recommendations of molec tumor board

@AVIVA1950
@Pharma_BI
@AdvancingPM

SESSION 2

Expanding the Precision Frontier

9:55-10:25

Precision Oncology in the Immunotherapy Era: Biomarkers and Clinical Trial Innovation

Razelle Kurzrock, MD

Lillian Siu, MD, President, AACR 2025-2026; Director, Phase I Clinical Trials Program; Co-Director, Robert and Maggie Bras and Family Drug Development Program Clinical Lead, Tumor Immunotherapy Program; BMO Chair, Precision Cancer Genomics, Princess Margaret Cancer Centre Professor of Medicine, University of Toronto

  • Princess Margaret CC went to Merck got pembrolizumab from them but built a team platform of clinicians and scientists to work on INSPIRE trial
  • $11 million of grants, 13 major papers, great team science
  • did ctDNA from liquid biopsy and also looked at methylation patterns in cfDNA
  • looked at IFN stimulation and outcome to pembrolizumab
  • retro transposable elements found in INSPIRE program, maybe a predictor of immune sensitivity
  • they were able to correlate some of their findings with spatial omics
  • using spatial data they could look at hot versus cold head and neck cancer
  •  factors for response to immunotherapy: TMB, t cell infiltrate,  PDL1 etc
  • using AI with IHC slides as well as NGS data sets
  • as clinical trials become multiomics and AI with multiomics platforms data sharing will be critical for success

10:25 – 10:35

The Microbiome and Its Role in Cancer Development and Treatment Response

Razelle Kurzrock, MD

Sabine Hazan, MD, CEO, Ventura Clinical Trials; CEO, Progenabiome

  • microbiome research at the infancy so we don’t know much when comes to oncology
  • we need to compare microbiome between persons using NGS and other omics
  • we all have different microbiome even though microbiome ‘healthy’
  • lots of factors affect microbiome including surgery
  • families are similar in their microbiome but when looking at Alzheimers there are differences
  • first lab to find whole COVID in the stools
  • virus was different in different people, difference spike proteins. Virus mutates from lung to stool (gut)
  • in intrafamily patients had different microbiome upon COVID infection
  • bifodobacteria was found as a major part of microbiome altered in COVID but also lots of other diseases
  • lots of examples of host microbial symbiosis
  • they had an instance with throat tumor treated with microbiome and tumor receded without chemo
  • in a glioblastoma microbiome adjustment helped but changed positive response to immunotherapy

Read Full Post »